Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Somnomed Limited ( (AU:SOM) ) is now available.
SomnoMed Limited has notified the market that 346,000 SOMAA options, which were due to expire on 24 June 2027 with an exercise price of $2.00, have lapsed as the conditions attached to these conditional rights were not satisfied. The cessation of these options, effective 31 December 2025, slightly reduces the company’s potential future issued capital and may marginally affect dilution expectations for existing shareholders, but does not directly alter current operations or cash position.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited is an ASX-listed medical device company (code: SOM) focused on sleep-related therapies, including oral appliance solutions for the treatment of obstructive sleep apnea and related sleep-disordered breathing conditions, serving patients and clinicians in sleep medicine markets globally.
Average Trading Volume: 108,383
Technical Sentiment Signal: Hold
Current Market Cap: A$163.6M
Learn more about SOM stock on TipRanks’ Stock Analysis page.